Related Experiment Video
Updated: Jan 29, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Partially hydrolyzed formula with high sn-2 palmitic acid on eosinophils and outcomes in preterm infants: PRIOR
Jialu Zhuang1, Ye Liu1, Qiongyu Liu2
1Department of Neonatology, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Insights
High sn-2 palmitic acid partially hydrolyzed formula (HPF) may reduce eosinophil-related inflammation in preterm infants. This study suggests HPF has potential for inflammation suppression without impacting hospital stay or necrotizing enterocolitis (NEC) incidence.
Area of Science:
- Neonatal immunology
- Pediatric gastroenterology
- Infant nutrition
Background:
- Preterm infants possess immature immune systems, increasing susceptibility to type 2 inflammation, characterized by eosinophil recruitment, which can worsen intestinal and respiratory inflammation.
- Breastfeeding offers anti-inflammatory benefits through sn-2 palmitic acid and immunomodulatory factors, but formula feeding is often clinically necessary.
- Partially hydrolyzed formula (HPF) with high sn-2 palmitic acid is hypothesized to mitigate eosinophil-related inflammation by reducing protein immunogenicity, though supporting evidence is limited.
Purpose of the Study:
- To evaluate the impact of high sn-2 palmitic acid partially hydrolyzed formula (HPF) on eosinophil counts and related inflammatory markers in preterm infants.
- To assess the safety and efficacy of HPF compared to standard preterm formula (SPF) regarding hospital stay duration and necrotizing enterocolitis (NEC) incidence.
Main Methods:
- A secondary analysis of the PRIOR randomized controlled trial (RCT) involving 90 preterm infants (<34 weeks gestational age or <2000g birth weight).
- Infants were randomized to receive either HPF (n=45) or SPF (n=45).
- Eosinophil counts, hospital stay duration, and NEC incidence were primary and secondary outcomes, analyzed using generalized additive models.
Main Results:
- Eighty infants completed the in-hospital phase; groups were comparable in baseline characteristics.
- A trend towards reduced eosinophil percentage was observed with HPF after prolonged exposure (>25 days, p=0.053), suggesting potential inflammation suppression.
- No significant differences were found in hospital stay duration (HPF: 30 days vs. SPF: 27 days) or NEC incidence (2.4% vs. 2.4%).
Conclusions:
- HPF shows promise in potentially reducing eosinophil-mediated inflammation in preterm infants.
- HPF did not significantly affect hospital stay duration or NEC incidence in this cohort.
- Further research is warranted to explore the long-term immune benefits of optimized preterm formulas like HPF.
Background:
Preterm infants, with immature immune systems, are susceptible to type 2 inflammation, characterized by eosinophil recruitment, exacerbating intestinal and respiratory inflammation. Breastfeeding mitigates inflammation via sn-2 palmitic acid and immunomodulatory factors (e.g., IL-10), but formula feeding is often necessary due to clinical constraints. High sn-2 palmitic acid partially hydrolyzed formula (HPF) may reduce eosinophil-related inflammation by lowering protein immunogenicity, yet evidence is limited.
Methods:
This secondary analysis of the ongoing PRIOR parallel-group randomized controlled trial (ChiCTR2400093296) (evaluating formula safety and growth-related outcomes) included 90 preterm infants (gestational age <34 weeks or birth weight <2000 g), randomized to HPF (n = 45) or standard preterm formula (SPF) (n = 45) using computer-generated randomization with allocation concealment. Infants were enrolled from 1 July 2024, to 30 June 2025, and followed weekly during hospitalization and monthly after discharge until a corrected age of 3 months. Primary outcomes were hematological parameters (including eosinophil counts) at discharge; secondary outcomes included hospital stay duration, necrotizing enterocolitis (NEC) incidence, and anemia management. Generalized additive models assessed eosinophil levels relative to corrected gestational age and formula exposure duration.
Results:
Eighty infants completed the in-hospital phase (HPF, n = 41; SPF, n = 39). Groups were similar in gestational age, birth weight, sex, and Apgar score (all p > 0.05). HPF showed a steeper decline trend in eosinophil percentage after prolonged exposure (>25 days, p = 0.053), suggesting inflammation suppression. Hospital stay duration (HPF, 30 (17-38) days vs. SPF, 27 (20-36) days; p = 0.825) and NEC incidence (2.4% vs. 2.4%; p = 1.000) did not differ significantly.
Conclusion:
HPF demonstrates potential in reducing eosinophil-mediated inflammation in preterm infants but has no significant impact on hospital stay or NEC incidence. This secondary analysis supports optimizing preterm formulas and warrants further investigation into long-term immune benefits.
Related Concept Videos
Molecular Compounds: Formulas and Nomenclature
Chemical Formulas
Ionic Compounds: Formulas and Nomenclature
Experimental Determination of Chemical Formula
Formula Mass and Mole Concepts of Compounds
Secondary Active Transport

